Sandhu Geeta, Adattini Josephine, Armstrong Gordon Evangeline, O'Neill Niamh, Bagnis Corrinne, Boddy Alan V, Chambers Pinkie, Flynn Alex, Hamilton Brett, Ibrahim Karim, Johnson David W, Karapetis Christos, Kelly Aisling, Kerr Kimberley-Ann, Kichenadasse Ganessan, Kliman David S, Kurkard Craig, Liauw Winston, Lucas Catherine, Mallett Andrew J, Malyszko Jolanta, McCaughan Georgia, Michael Michael, Mirkov Sanja, Morris Emma, Pollock Carol A, Roberts Darren M, Routledge David J, Scuderi Carla, Shingleton Julia, Shortt Jake, Siderov Jim, Sprangers Ben, Stein Brian N, Tey Amanda, Webber Kate, Wichart Jenny, Wong Rachel, Ward Robyn L
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
eviQ, Cancer Institute NSW, St Leonards, NSW, Australia.
EClinicalMedicine. 2025 Mar 25;82:103161. doi: 10.1016/j.eclinm.2025.103161. eCollection 2025 Apr.
Part 2 of the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) offers drug-specific consensus recommendations based on both evidence and practical experience. These recommendations build upon the kidney function assessment and classification guidelines established in Part 1 of ADDIKD. Here we illustrate how dosing recommendations differ between ADDIKD and existing guidance for four commonly used drugs: methotrexate, cisplatin, carboplatin and nivolumab. We then describe how the recommendations can be distilled into practice points for methotrexate and cisplatin. While ADDIKD is a significant improvement from previous guidelines, adoption of this new guideline requires further endorsement from key external stakeholders, 'change championing' by clinicians locally and encouraging its integration into existing reference sources, clinical trial protocols and electronic prescribing systems.
Development of the ADDIKD guideline is funded by the NSW Government as part of the Cancer Institute NSW and received no funding from external commercial sources.
《肾功能不全患者抗癌药物剂量国际共识指南》（ADDIKD）的第2部分基于证据和实践经验提供了特定药物的共识性建议。这些建议建立在ADDIKD第1部分确立的肾功能评估和分类指南之上。在此，我们阐述了ADDIKD与四种常用药物（甲氨蝶呤、顺铂、卡铂和纳武单抗）现有指南在给药建议方面的差异。然后，我们描述了如何将这些建议提炼为甲氨蝶呤和顺铂的实践要点。虽然ADDIKD相比之前的指南有显著改进，但采用这一新指南需要关键外部利益相关者的进一步认可、临床医生在当地的“变革倡导”，并鼓励将其纳入现有参考资料、临床试验方案和电子处方系统。
ADDIKD指南的制定由新南威尔士州政府资助，作为新南威尔士州癌症研究所的一部分，未接受外部商业来源的资金。
